# Pfizer Achieves Study Endpoint for ELREXFIO and FDA Expands TALZENNA Approval

- Published: 2026-11-09 04:22 UTC
- Section: Life & Health › Medicine
- Tags: Pfizer, cancer drugs, FDA approval, business growth, clinical trials
- URL: https://realtech.media/news/rt-8c24c2f0155ae79d99aee737_pfizer_achieves_study/

**Pfizer reports a study endpoint achievement for ELREXFIO and an expanded FDA approval for TALZENNA, impacting growth perspectives.**

![Pfizer Achieves Study Endpoint for ELREXFIO and FDA Expands TALZENNA Approval](https://realtech.media/media/2026/11/e371744b4481e366.webp)
*ad-hoc-news.de*

On October 27, Pfizer announced that it has reached a study endpoint for ELREXFIO. This follows the company's announcement the day before regarding an expanded FDA approval for TALZENNA in combination with XTANDI. The combination is seen as favorable for valuation, provided that clinical results and broader applications yield economic benefits.

## Study Endpoint and Regulatory Developments

The two announcements pertain to different stages of development. For ELREXFIO, Pfizer plans to submit study data to health authorities worldwide. In contrast, the expanded approval for the combination of TALZENNA and XTANDI has already been granted by the FDA.

Investors must weigh two distinct questions: the ongoing regulatory development of one drug and the economic utilization of the expanded approval of the other. This distinction influences how much confidence investors can place in the progress made. An optimistic outlook assumes that Pfizer successfully advances both development paths.

## Economic Implications of Approvals

The central factor is the conversion of medical advancements into additional business. According to Pfizer, the Phase 3 study MagnetisMM-32 for ELREXFIO achieved its primary endpoint of progression-free survival, focusing on patients with relapsed or refractory multiple myeloma. This provides a clinical basis for the planned submission.

For TALZENNA and XTANDI, the FDA decision pertains to specific men with HRR-gene altered metastatic hormone-sensitive prostate cancer. The expansion allows for use in an earlier treatment setting and is based on data from the Phase 3 study TALAPRO-3.

Both developments gain significance for investors if Pfizer can develop broader economic utilization from them. The decisive benchmark would then be the actual business contribution. Those evaluating the stock based on this perspective are betting on a transition from medical progress to financially relevant growth.

The positive scenario connects the already granted approval expansion with further advancements for ELREXFIO. If Pfizer can expedite the planned submission and subsequent regulatory decisions are favorable, the economic outlook for the drug could improve. Concurrently, the earlier treatment setting for TALZENNA and XTANDI could open additional business opportunities if the combination is utilized accordingly.

The financial reference point is provided by the results released on Tuesday, with Pfizer reporting a revenue of $16.6 billion for Q3 2026 and an adjusted diluted earnings per share of $0.87. For a more favorable assessment, the cancer drugs would need to contribute to business development beyond individual success announcements. This would be particularly compelling if regulatory progress and economic implementation coincide. Under this condition, investors could assign a higher value to clinical results for future profitability.

## Sources

1. [ad-hoc-news.de](https://www.ad-hoc-news.de/boerse/news/unternehmensnachrichten/pfizer-aktie-fda-erweitert-zulassung-fuer-talzenna/70478741)

---

Source: RealTech, realtech.media — https://realtech.media/news/rt-8c24c2f0155ae79d99aee737_pfizer_achieves_study/